One Drug, Three Organs: Dupilumab Calms a Child’s Atopic Dermatitis, Asthma and Eosinophilic Esophagitis

When a seven-year-old girl arrived at a pediatric clinic in Shanghai, her medical record read like a catalogue of modern allergic disease. She had endured more than four years of relentless, itching dermatitis that covered her neck, trunk and limbs. She suffered five to six wheezing episodes a year, twice landing in hospital with acute asthma attacks. And for a full year she had battled intermittent vomiting that no one could fully explain. What followed, according to a case report published in Frontiers in Allergy, was a striking demonstration of what happens when doctors treat the underlying immunological circuitry rather than each organ in isolation: a single antibody, dupilumab, produced measurable improvement in her skin, her lungs and her gut over 48 weeks of therapy.

The biological logic behind this multisystem response rests on a shared molecular pathway. Atopic dermatitis, asthma and eosinophilic esophagitis tend to travel together, a clustering sometimes described as atopic multimorbidity, because all three are driven by type 2 inflammation, an immune program characterized by the signaling molecules interleukin-4 and interleukin-13. These cytokines promote IgE antibody class switching, recruit eosinophils, disrupt epithelial barriers and, in the airways, increase hyperresponsiveness. Dupilumab, a fully human IgG4 monoclonal antibody, blocks the interleukin-4 receptor alpha subunit and thereby silences signaling from both IL-4 and IL-13 at once. Instead of suppressing inflammation broadly, as systemic steroids do, it targets a single convergence point shared by several apparently distinct diseases.

The girl’s baseline assessment underscored how severe her condition had become. Her chart-recorded SCORAD score, a composite measure of atopic dermatitis extent and intensity, stood at 104, and her combined itch and sleep rating was 12. Total serum IgE, a marker of allergic sensitization, exceeded 2,000 IU/mL, with the strongest responses directed against house dust mites and additional sensitivities to animal danders, pollens and foods. Topical desonide ointment, tacrolimus and oral cetirizine had all failed to bring the disease under control. In August 2024, upper endoscopy revealed the gastrointestinal dimension of her illness: esophageal biopsies contained more than 100 eosinophils per high-power field, a density that firmly supported a diagnosis of eosinophilic esophagitis, while lower but abnormal eosinophil counts appeared in biopsies from the stomach, terminal ileum and colon.

Those lower-density findings demanded careful interpretation, and the report is unusually candid about the uncertainty. Counts of 5 to 10 eosinophils per high-power field in the stomach and sigmoid colon, and 20 to 30 in the transverse colon, did not uniformly satisfy the thresholds proposed for a definite diagnosis of non-esophageal eosinophilic gastrointestinal disease. The authors therefore described the extraesophageal findings as gastrointestinal eosinophilic infiltration rather than a confirmed multi-segment eosinophilic gastrointestinal disorder. This distinction matters scientifically. Diagnostic criteria for these conditions are still evolving, and eosinophil densities vary naturally with anatomy, so over-diagnosis carries real consequences for how treatment effects are judged.

The primary indication for starting dupilumab was the severe, treatment-refractory dermatitis, with the coexisting asthma and eosinophylic esophagitis reinforcing the choice of a pathway-directed therapy. On February 27, 2025, after informed consent from her guardian, she received a 600-mg loading dose followed by 300 mg injected subcutaneously every four weeks, fourteen injections in all. Within the first weeks, the trajectory of her disease began to bend. By week 16, the recorded SCORAD had fallen from 104 to 36, the investigator’s global assessment had improved from 3 to 2, and the itch and sleep score had dropped from 12 to 4. By week 48, pruritus had resolved entirely, skin lesions were markedly improved, and topical anti-inflammatory treatment could be stopped altogether, leaving only intermittent cetirizine drops.

The respiratory benefits were equally tangible. Over the entire follow-up period, no recurrent wheezing was reported, although an occasional cough persisted. Spirometry performed in December 2025 was normal, with forced expiratory volume in one second measuring 108.5 percent of predicted and the FEV1-to-FVC ratio at 103.6 percent. Perhaps most telling for a child previously hospitalized twice in a single year, her inhaled salmeterol/fluticasone therapy was progressively reduced to a single inhalation every two days. The authors note, appropriately, that without a complete baseline spirometric dataset and with controller therapy still in use, respiratory improvement cannot be attributed to dupilumab alone.

The gastrointestinal story was more nuanced. Appetite improved, vomiting ceased, and abdominal pain and distension disappeared. A follow-up endoscopy roughly 24 weeks into treatment showed smooth esophageal mucosa and no obvious duodenal abnormality, a marked change from the pre-treatment findings. Yet the gastric fundus and antrum remained congested and edematous, with erosions and multiple small antral ulcers persisting, and repeat biopsies were unavailable. Because intravenous omeprazole and methylprednisolone had been given during the acute gastrointestinal episode in August 2024, some six months before dupilumab began, and proton-pump inhibitor therapy continued alongside it, the case supports a possible independent gastrointestinal benefit but cannot prove histological remission attributable to the antibody. The authors are explicit that symptom improvement was not confirmed by repeat biopsy.

Objective biomarkers traced the systemic shift in her immune state. Total IgE collapsed from more than 2,000 IU/mL to 211.2 IU/mL, and a panel of allergen-specific IgE values, including those against dust mites, cat dander, egg and peanut, fell in parallel. Peripheral eosinophil counts dropped from 0.64 to 0.30 × 10⁹/L, although the decline was not linear; counts transiently rose to 0.80 × 10⁹/L in April 2025 before settling downward. Notably, no treatment-related adverse events or interruptions occurred across the 48 weeks. The authors caution, however, that falling IgE and eosinophils indicate biological modulation of type 2 inflammation but are not established biomarkers of clinical response, particularly in eosinophilic gastrointestinal disease, where organ-specific outcomes remain the primary evidence of therapeutic effect.

The broader significance of the report lies in its support for an umbrella strategy: treating several coexisting type 2 inflammatory diseases with one pathway-directed drug. Randomized phase 3 evidence already shows that weekly dupilumab improves both histological and symptomatic outcomes in adolescents and adults with eosinophilic esophagitis, and retrospective series and pediatric reports have described symptomatic and histological improvement in eosinophilic gastritis, duodenitis, gastroenteritis and colitis. A single case cannot settle the question of efficacy in non-esophageal disease, and the limitations here are considerable: a retrospective single-patient design, concomitant steroid and proton-pump inhibitor therapy, missing biopsy-level details, the absence of validated eosinophilic esophagitis endoscopic scoring, and the use of an adult quality-of-life instrument rather than the age-appropriate pediatric version. Still, the family reported that relief from itching, wheezing, vomiting and poor appetite substantially reduced the child’s daily symptom burden and simplified her treatment regimen.

For clinicians and researchers, the case adds a carefully documented pediatric data point to a fast-growing literature on IL-4 and IL-13 blockade as a unifying therapeutic principle. It illustrates both the promise and the epistemic limits of the approach: serial scores, photographs, spirometry, endoscopy and longitudinal biomarkers can chart a patient’s improvement across organ systems, but without repeat histology and adequate controls, attribution remains probabilistic. What the report does establish is feasibility and safety over nearly a year of treatment in a young child carrying an unusually heavy allergic burden, along with a template for how future studies might rigorously test whether drugs targeting shared cytokine pathways can genuinely act as one therapy for many diseases. If larger, biopsy-confirmed trials bear out what this single child’s course suggests, the era of treating atopic multimorbidity as one disease expressed in many organs may be drawing closer.

Subject of Research: Dupilumab treatment of coexisting atopic dermatitis, asthma and eosinophilic esophagitis in a child with type 2 inflammation

Article Title: Case Report: Multisystem response to dupilumab in a child with atopic dermatitis, asthma, eosinophilic esophagitis, and other gastrointestinal manifestations

Article References: Yan, H.-J., Dong, W., Yang, Y.-N., & Zeng, C.-Y. (2026). Case Report: Multisystem response to dupilumab in a child with atopic dermatitis, asthma, eosinophilic esophagitis, and other gastrointestinal manifestations. Frontiers in Allergy, 7, Article 1929466. https://doi.org/10.3389/falgy.2026.1929466

Image Credits: AI Generated

DOI: 10.3389/falgy.2026.1929466

Keywords: dupilumab, atopic dermatitis, asthma, eosinophilic esophagitis, eosinophilic gastrointestinal disease, type 2 inflammation, interleukin-4, interleukin-13, IgE, eosinophils, pediatrics, case report